- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05270200
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation:A Multicenter, Single-arm Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Study Drug:
Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better.
Chidamide exhibits potent inhibitory effect on cell viability of MDS and AML cells, and the possible mechanism may lie in the downregulation of JAK2/STAT3 signaling through SOCS3 upregulation.
Study Group: If you are found to be eligible to take part in this study,you will receive azacitidine and chidamide.
Study Drug Administration:
You will recieve six courses of azacitidine through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time you will recieve oral chidamide per day for no more than 2 years.
The treatment will start after 60 days post-transplantation and your neutrophil count is of 1.5 × 10⁹ cells per L or higher and non-transfused platelets is of 80 × 10⁹ per L or higher.
The treatment would stop if neutrophil count is less than 0.5 × 10⁹ cells per L or platelets is less than 20 × 10⁹ per L.And it would also stop when grade 3/4 non-hematological adverse events happened.
Study Visit:
You may come back for study visits every month in a year when the treatment start.
Blood and urine will be drawn for routine tests every month. At 1,2,3,4,5,6,9 and 12 months,You will have a bone marrow aspiration to check the status of the disease.
You will have a electrocardiiogram test every 3 months to check the heart function.
Length of Study:
You will be on study treatment for up to 1 year.You will be taken off study early if you experience intolerable side effects or the disease gets worse.
End-of-Treatment Visit:
If you complete the planned treatment with azacitidine and chidamide, you will have an end-of-treatment visit:
Blood and urine will be drawn for routine tests. You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function.
This is an investigational study. Azacitidine and chidamide are FDA approved and are commercially available for the treatment of acute leukemia.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Rui Huang, Doctor
- Phone Number: +8615918528317
- Email: Rachelchn@163.com
Study Contact Backup
- Name: Yunqing Wang, Bachelor
- Phone Number: +8618585509970
- Email: Wangyun7q@163.com
Study Locations
-
-
Guandong
-
Guanzhou, Guandong, China, 510250
- Recruiting
- Nanfang Hospital of Southern Medical University
-
Contact:
- Rui Huang, Doctor
- Phone Number: +8615918528317
- Email: Rachelchn@163.com
-
Contact:
- Yunqing Wang, Bachelor
- Phone Number: +8618585509970
- Email: Wangyun7q@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1.Age 18 to 60 years old,both male and female
- 2.Be able to understand and sign informed consent
- 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic
- 4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML
- 5.Patients with an ECOG performance status 0,1,2 or 3
- 6.Expected survival time ≥ 3 months
- 7.Non-hematological toxicity related to transplantation does not exceed Grade 2
8.Laboratory indicators meet the following standards:
- 7 days before the first day of the first course of treatment, bilirubin, ALT and AST were all less than 3 times the upper limit of normal.
- Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the neutrophil count are greater than 1.5×10/L and without G-CSF treatment.
- Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, platelet count greater than 80×10/L and without platelet transfusion.
- Serum creatinine clearance rate is greater than 30ml/min.
Exclusion Criteria:
- 1.Uncontrollable active infection
- 2.Patients with active hepatitis B or C or HIV infection before enrollment
- 3.Have a grade III-IV graft-versus-host disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azacitidine combined with Chidamide
Patients will recieve six courses of azacitidine 100mg through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time patients will recieve oral chidamide 5mg per day for no more than 2 years.
|
Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
Other Names:
Patients will recieve oral chidamide 5mg per day for no more than 2 years.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Paticipants With Adverse Events as a Measure of Safety
Time Frame: From the day of stem cell transplantation to one year after stem cell transplantation
|
Safety were measured with respect to:
|
From the day of stem cell transplantation to one year after stem cell transplantation
|
One year cumulative incidence of relapse
Time Frame: From the day of stem cell transplantation to one year after stem cell transplantation
|
Leukemia relapse base on morphoogy criterion
|
From the day of stem cell transplantation to one year after stem cell transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapes-free Survival(RFS)
Time Frame: From the day of stem cell transplantation to one year after stem cell transplantation
|
The time that a participant survives without relapes of the disease
|
From the day of stem cell transplantation to one year after stem cell transplantation
|
Overall survival(OS)
Time Frame: From the day of stem cell transplantation to one year after stem cell transplantation
|
The time that a participant survives without death
|
From the day of stem cell transplantation to one year after stem cell transplantation
|
The cumulative Incidence rate of GVHD
Time Frame: From the day of stem cell transplantation to one year after stem cell transplantation
|
acute GVHD and chronic GVHD diagnosis based on MIH criterion
|
From the day of stem cell transplantation to one year after stem cell transplantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rui Huang, Doctor, Zhujiang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AZA+Chidamide
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid, Acute
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
TJ Biopharma Co., Ltd.Recruiting
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamRecruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
-
CelgeneCompletedMyelodysplastic SyndromesUnited States